These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 35763342)

  • 21. Specific psychiatric manifestations among preclinical Huntington disease mutation carriers.
    Marshall J; White K; Weaver M; Flury Wetherill L; Hui S; Stout JC; Johnson SA; Beristain X; Gray J; Wojcieszek J; Foroud T
    Arch Neurol; 2007 Jan; 64(1):116-21. PubMed ID: 17210818
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Understanding patient-reported outcome measures in Huntington disease: at what point is cognitive impairment related to poor measurement reliability?
    Carlozzi NE; Schilling S; Kratz AL; Paulsen JS; Frank S; Stout JC
    Qual Life Res; 2018 Oct; 27(10):2541-2555. PubMed ID: 29909483
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A clinical classification acknowledging neuropsychiatric and cognitive impairment in Huntington's disease.
    Vinther-Jensen T; Larsen IU; Hjermind LE; Budtz-Jørgensen E; Nielsen TT; Nørremølle A; Nielsen JE; Vogel A
    Orphanet J Rare Dis; 2014 Jul; 9():114. PubMed ID: 25026978
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data.
    Tabrizi SJ; Scahill RI; Owen G; Durr A; Leavitt BR; Roos RA; Borowsky B; Landwehrmeyer B; Frost C; Johnson H; Craufurd D; Reilmann R; Stout JC; Langbehn DR;
    Lancet Neurol; 2013 Jul; 12(7):637-49. PubMed ID: 23664844
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Responsiveness to change over time and test-retest reliability of the PROMIS and Neuro-QoL mental health measures in persons with Huntington disease (HD).
    Carlozzi NE; Boileau NR; Roché MW; Ready RE; Perlmutter JS; Chou KL; Barton SK; McCormack MK; Stout JC; Cella D; Miner JA; Paulsen JS
    Qual Life Res; 2020 Dec; 29(12):3419-3439. PubMed ID: 32813263
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data.
    Tabrizi SJ; Reilmann R; Roos RA; Durr A; Leavitt B; Owen G; Jones R; Johnson H; Craufurd D; Hicks SL; Kennard C; Landwehrmeyer B; Stout JC; Borowsky B; Scahill RI; Frost C; Langbehn DR;
    Lancet Neurol; 2012 Jan; 11(1):42-53. PubMed ID: 22137354
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Severity of cognitive impairment in juvenile and late-onset Huntington disease.
    Gómez-Tortosa E; del Barrio A; García Ruiz PJ; Pernaute RS; Benítez J; Barroso A; Jiménez FJ; García Yébenes J
    Arch Neurol; 1998 Jun; 55(6):835-43. PubMed ID: 9626775
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Visual Object Perception in Premanifest and Early Manifest Huntington's Disease.
    Coppen EM; Jacobs M; van der Zwaan KF; Middelkoop HAM; Roos RAC
    Arch Clin Neuropsychol; 2019 Nov; 34(8):1320-1328. PubMed ID: 30796801
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Do I misconstrue? Sarcasm detection, emotion recognition, and theory of mind in Huntington disease.
    Larsen IU; Vinther-Jensen T; Gade A; Nielsen JE; Vogel A
    Neuropsychology; 2016 Feb; 30(2):181-9. PubMed ID: 26301773
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Huntington disease: natural history, biomarkers and prospects for therapeutics.
    Ross CA; Aylward EH; Wild EJ; Langbehn DR; Long JD; Warner JH; Scahill RI; Leavitt BR; Stout JC; Paulsen JS; Reilmann R; Unschuld PG; Wexler A; Margolis RL; Tabrizi SJ
    Nat Rev Neurol; 2014 Apr; 10(4):204-16. PubMed ID: 24614516
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cognition in Huntington's disease in manifest, premanifest and converting gene carriers over ten years.
    Hart EP; Dumas EM; Giltay EJ; Middelkoop HA; Roos RA
    J Huntingtons Dis; 2013; 2(2):137-47. PubMed ID: 25063511
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Digital Devices for Assessing Motor Functions in Mobility-Impaired and Healthy Populations: Systematic Literature Review.
    Guo CC; Chiesa PA; de Moor C; Fazeli MS; Schofield T; Hofer K; Belachew S; Scotland A
    J Med Internet Res; 2022 Nov; 24(11):e37683. PubMed ID: 36409538
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diagnostic criteria for Huntington's disease based on natural history.
    Reilmann R; Leavitt BR; Ross CA
    Mov Disord; 2014 Sep; 29(11):1335-41. PubMed ID: 25164527
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Smartphone monitoring of cognition in people with multiple sclerosis: A systematic review.
    Foong YC; Bridge F; Merlo D; Gresle M; Zhu C; Buzzard K; Butzkueven H; van der Walt A
    Mult Scler Relat Disord; 2023 May; 73():104674. PubMed ID: 37001409
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tapping linked to function and structure in premanifest and symptomatic Huntington disease.
    Bechtel N; Scahill RI; Rosas HD; Acharya T; van den Bogaard SJ; Jauffret C; Say MJ; Sturrock A; Johnson H; Onorato CE; Salat DH; Durr A; Leavitt BR; Roos RA; Landwehrmeyer GB; Langbehn DR; Stout JC; Tabrizi SJ; Reilmann R
    Neurology; 2010 Dec; 75(24):2150-60. PubMed ID: 21068430
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Altered driving performance of symptomatic Huntington's disease gene carriers in simulated road conditions.
    Jacobs M; Hart EP; Miranda YM; Groeneveld GJ; van Gerven JMA; Roos RAC
    Traffic Inj Prev; 2018; 19(7):708-714. PubMed ID: 30273496
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Validation of biomarkers in Huntington disease to support the development of disease-modifying therapies: A systematic review and critical appraisal scheme.
    Tang H; van Eimeren T; Sampaio C; Mestre TA
    Parkinsonism Relat Disord; 2021 Dec; 93():89-96. PubMed ID: 34864305
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Monitoring the Motor Phenotype in Huntington's Disease by Analysis of Keyboard Typing During Real Life Computer Use.
    Lang C; Gries C; Lindenberg KS; Lewerenz J; Uhl S; Olsson C; Samzelius J; Landwehrmeyer GB
    J Huntingtons Dis; 2021; 10(2):259-268. PubMed ID: 33459656
    [TBL] [Abstract][Full Text] [Related]  

  • 39. End-of-life measures in Huntington disease: HDQLIFE Meaning and Purpose, Concern with Death and Dying, and End of Life Planning.
    Carlozzi NE; Boileau NR; Paulsen JS; Perlmutter JS; Lai JS; Hahn EA; McCormack MK; Nance MA; Cella D; Barton SK; Downing NR
    J Neurol; 2019 Oct; 266(10):2406-2422. PubMed ID: 31190171
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Magnetic resonance spectroscopy biomarkers in premanifest and early Huntington disease.
    Sturrock A; Laule C; Decolongon J; Dar Santos R; Coleman AJ; Creighton S; Bechtel N; Reilmann R; Hayden MR; Tabrizi SJ; Mackay AL; Leavitt BR
    Neurology; 2010 Nov; 75(19):1702-10. PubMed ID: 21060093
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.